RPL13A

Across TCGA pan-cancer cohorts, RPL13A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPL13A data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RPL13A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RPL13A expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and GBM are the cancer types where RPL13A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.947	0.640	.004	13	view →
LUAD	DFS	Quartile	All	0.835	0.457	.014	10	view →
GBM	OS	Quartile	All	0.677	0.218	<.001	6	view →
UCEC	DFS	Tertile	All	0.915	0.757	.044	4	view →
HNSC	DFS	Median	All	0.743	0.563	.024	2	view →
CCRCC	OS	Median	All	0.789	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPL13A–LSCC (OS)

Open the LSCC breakdown →